Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).

Phase 2

Completed

• Conditions: Pulmonary Hypertension
• Interventions: Drug: Hymecromone (H01); Drug: Placebo

• Registration Number: NCT05128929
• Lead Sponsor: Stanford University

Brief Summary

This study is a prospective, randomized, double-blind, study of H01 (Hymecromone) in adults with pulmonary hypertension (PH). The primary objective of this study is to evaluate the safety and tolerability of oral H01 and the potential benefit of oral H01 on clinical measures of PH disease severity over 24 weeks.

Study Hypothesis:

Oral H01, at doses of 1600 mg per day, will be a safe and well-tolerated agent in adults with pulmonary hypertension over 24 weeks

Detailed Description

The study's objectives are to evaluate:

* The changes in clinical and functional measures (pulmonary function test, pulmonary vascular resistance, mean pulmonary arterial pressure, and 6 Minute Walk Distance Test) in adults with PH treated with oral H01

* The safety and tolerability of the use of oral H01 for PH over 24 weeks using health criteria/evaluations (Common Terminology Criteria for Adverse Events (CTCAE), quality of life (QOL) score, EMPHASIS-10 score and St George Respiratory Questionnaire (SGRQ) score)

* To investigate the clinical efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) markers (serum HA concentration, inflammatory markers and cytokines, NT-proBNP, and H01 and metabolite serum concentrations) in this population following oral H01 use

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2021-11-11
• Study First Submitted QC: 2021-11-11
• Study First Posted: 2021-11-22
• Study Start: 2022-04-01
• Primary Completion: 2023-09-21
• Study Completion: 2023-09-29
• Results First Submitted: 2024-09-22
• Status Verified: 2024-10
• Results First Submitted QC: 2024-10-31
• Last Update Submitted: 2024-10-31
• Results First Posted: 2024-11-26
• Last Update Posted: 2024-11-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

1. Classified as WHO functional class II/III/IV despite treatment with maximally tolerated doses of 2 or more treatment modalities (exp. PDE5 inhibitors, guanylate cyclase stimulators, endothelin receptor antagonists, and prostanoids)

2. Baseline 6MWT: greater than 100 meters and less than 550 meters

3. Established diagnosis of Group 3 pulmonary hypertension as a result of interstitial lung disease OR established diagnosis of Group 1 pulmonary hypertension as a result of connective tissue disease, idiopathic, hereditary, drugs, or toxins.

4. Right heart catheterization at randomization showing pre-capillary pulmonary hypertension (mPAP ≥ 25 mmHg and PVR > 400 dynes * sec * cm^ -5) and:

   • PCWP ≤20 mmHg for Group 3 PH patients and Group 1 PAH patients

5. Participants on chronic medication for PAH, PH, or underlying lung disease must be on a stable and optimized dose for at least 90 days prior to the first dose of the study drug.

6. Female participants who are heterosexually active must use an acceptable method of contraception: condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, IUD, or Hormone-based contraceptive

7. Be able to provide written informed consent and comply with study requirements

8. Be able to read, speak and understand English

Read More

Exclusion Criteria

1. Participants with a diagnosis of PAH or PH for reasons due to any of the following:

   • Group 2, 4, or 5

   • Group 1 due to HIV, veno-occlusive disease, porto-pulmonary hypertension, congenital heart disease

   • Group 3 due to severe chronic obstructive pulmonary disease (COPD) or obstructive sleep apnea (OSA)

     • Note: participants with overlapping syndromes will be evaluated on a case-by-case basis by the recruiting physician*

2. Total Lung Capacity (TLC) less than 60% predicted

3. FEV1/FVC less than 50% predicted or FEV1 less than 55% predicted

4. Inability to safely attempt completion of the 6MWD test

5. Use of experimental PAH treatments within the past 3 months

6. Current systemic treatment with hymecromone

7. Left sided heart disease as defined by either a PCWP greater than 20 mmHg and/or left ventricular ejection fraction less than 40%

   • Note: participants with abnormal left ventricular function attributable entirely to impaired left ventricular filling due to the effects of right ventricular overload (ie right ventricular hypertrophy and/or dilatation) are not excluded

8. Participants must not have 3 or more of the following left ventricular disease / dysfunction risk factors:

   • Body mass index (BMI) greater than 30kg/m2
   • History of essential hypertension requiring medication
   • Diabetes mellitus

9. Historical evidence of significant coronary disease established by any of the following:

   • History of myocardial infarction
   • History of percutaneous coronary intervention or coronary artery bypass graft
   • Angiographic evidence of greater than 50% stenosis in at least one coronary artery
   • Positive stress test with imaging
   • Stable angina

10. Significant valvular heart disease as determined by more than moderate findings on echocardiogram or history of valve replacement

11. Pregnant or actively breastfeeding

12. Female participants with childbearing potential not willing to use a form of birth control (including abstinence) during the study

13. Inability to undergo right heart catheterization

14. Acute pulmonary embolism within 90 days of randomization

15. Exacerbation of underlying lung disease or active pulmonary or upper respiratory infection within 30 days of randomizations

16. Use of any inhaled tobacco products or significant history of drug abuse within 3 months prior to randomization

17. Subject is receiving greater than 10L/min of oxygen supplementation by any mode of delivery at rest at baseline

18. Body mass index greater than 40kg/m2

19. Participants with history of dysphagia, achalasia, or difficulty swallowing capsules, tablets or pills

20. Participants with liver failure or AST or ALT greater than 2 times the upper limit of normal

21. Participants with total bilirubin levels greater than 2 times the upper limit of normal

22. Participants with CrCl less than 45

23. Use of any investigational drug/device, or participation in any investigational study with therapeutic intent within 30 days prior to randomization

24. Known allergy to hymecromone or any component thereof

25. Known allergy to any component of placebo (including wheat allergy, celiac disease, rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption)

26. Physician concern that participant may not adhere to the study protocol

27. Significant psychiatric, addictive, or other disorder that compromises the subject's ability to provide informed consent

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental Treatment Oral Hymecromone (H01)	Hymecromone (H01)	Treatment will be initiated. Participants will be administered 800 mg of oral H01 two times a day (total dose: 1600 mg/day). Participants will continue to be on treatment for 24 weeks and will be monitored with assessments.
Placebo	Placebo	Participants randomized to placebo will receive oral tablet placebo (inactive ingredients) two times a day. Participants will continue to be on placebo for 24 weeks and will be monitored with assessments.

Primary Outcome Measures

Name	Time	Method
Calculated Pulmonary Vascular Resistance (PVR)	Baseline to end of treatment (Week 24; +/- 7 days)	Calculated pulmonary vascular resistance (PVR) measured by right heart catheterization (RHC).; A normal PVR ranges between 0.25 and 1.6 wood units (WU). Pre-capillary pulmonary hypertension is characterized by a PVR greater than 3 WU. Greater PVR is indicative of increased disease severity.; Either Fick or Thermodilution method can be utilized to measure cardiac output (CO) and calculate PVR. Fick method utilizes estimated oxygen consumption to measure CO and calculate PVR, while the thermodilution method utilizes temperature change to measure CO and calculate PVR.; All measurements to calculate PVR were obtained at end-expiration (measuring the pressures at functional residual capacity of the lungs).

Secondary Outcome Measures

Name	Time	Method
Serum Hyaluronan (HA) Concentration	Baseline and end of treatment (Week 24; +/- 7 days)	Two samples were collected at each time point and mean values were calculated. The average of the two mean values is reported.; The normal adult circulating level of hyaluronan ranges between 10 and 100 ng/mL.
Number of Participants With Adverse Events by Severity Using the NIH Common Terminology Criteria for Adverse Events (CTCAE) as a Measure of Safety and Tolerability of H01 in Adults With Pulmonary Hypertension	Baseline to end of treatment (Week 24; +/- 7 days)	* Grade 1: Mild asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.; * Grade 2: Moderate minimal, local or noninvasive intervention indicated; limiting age- appropriate instrumental activities of daily living (ADL).; * Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL.; * Grade 4: Life-threatening consequences; urgent intervention indicated.; * Grade 5: Death related to AE.
Mean Pulmonary Arterial Pressure (mPAP)	Baseline and end of treatment (Week 24; +/- 7 days)	Mean pulmonary arterial pressure (mPAP) measured by RHC.; A normal mPAP ranges between 9 and 19 mmHg at rest. Pre-capillary pulmonary hypertension is characterized by a mPAP greater than 20 mmHg at rest. Greater mPAP is indicative of increased disease severity.; All measurements were obtained at end-expiration.
6 Minute Walk Distance Test (6 MWDT)	Screening (up to 30 days prior to baseline) and weeks 4 (+/- 3 days), 12 (+/- 3 days), and 24 (+/- 7 days).	The 6MWDT (distance walked in 6 minutes) is used to determine functional exercise capacity, assess treatment efficacy, predict prognosis, and establish rehabilitation programs in PAH/PH patients.
EMPHASIS-10 Scale Score	Baseline and weeks 4 (+/- 3 days), 12 (+/- 3 days), and 24 (+/- 7 days)	Quality of life (QOL) assessed using the EMPHASIS-10 questionnaire.; The minimum score for this questionnaire is 0. The maximum score for this questionnaire is 50. Higher scores are indicative of poorer health-related quality of life (HRQoL) due to pulmonary hypertension.
St George Respiratory Questionnaire (SGRQ) Scale Score	Baseline and weeks 4 (+/- 3 days), 12 (+/- 3 days), and 24 (+/- 7 days)	Quality of life (QOL) assessed using the St George Respiratory Questionnaire (SGRQ).; There are a total of 3 components in the questionnaire, including symptoms, activity, and impacts. Each component has a minimum weight of 0, and a maximum weight of 662.5, 1209.1, and 2117.8, respectively. The minimum weight of the total score (combining all 3 components) is 0, and the maximum weight of total score is 3989.4.; The total score is calculated by dividing the summed weights from positive items in the questionnaire by the sum of weights for all items in the questionnaire and multiplying this by 100. The minimum total score is 0, the maximum is 100.; Lower scores indicate better health status.
N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)	Baseline and weeks 4 (+/- 3 days), 12 (+/- 3 days), and 24 (+/- 7 days)	N-terminal pro-brain-type natriuretic peptide (NT-proBNP) is laboratory test used for assessing disease severity in pulmonary hypertension.; The normal ranges for NT-proBNP are as follows: Male (Reflects 95th percentile w/o CHF ): 18-\<44 yr: 36-93 pg/mL 44-\<54 yr: 36-138 pg/mL 54-\<64 yr: 36-177 pg/mL 64-\<74 yr: 36-229 pg/mL 74 yr: 36-852 pg/mL; Females (Reflects 95th percentile w/o CHF ): 18-\<44 yr: 36-178 pg/mL 44-\<54 yr: 36-192 pg/mL 54-\<64 yr: 36-226 pg/mL 64-\<74 yr: 36-353 pg/mL \>74 yr: 36-624 pg/mL

Trial Locations

Locations (1)

Stanford University School of Medicine; 🇺🇸 Stanford, California, United States